Almonertinib
- Generic Name
- Almonertinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H35N7O2
- CAS Number
- 1899921-05-1
- Unique Ingredient Identifier
- T4RS462G19
- Background
Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations. It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
- Indication
1.用于既往经表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M 突变阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗。
2.用于表皮生长因子受体（EGFR）敏感突变阳性局部晚期或转移性非小细胞肺癌（NSCLC）患者一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: chemotherapyDrug: Almonertinib
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT04951648
- Locations
- 🇨🇳
Sun yat-sen Univerisity Cancer Center, Guangzhou, Guangdong, China
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT04951635
- Locations
- 🇨🇳
Shandong Cancer Hospital, Ji'nan, Shandong, China
Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Yuan Chen
- Target Recruit Count
- 26
- Registration Number
- NCT04952168
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis
- Conditions
- EGFR Activating MutationNSCLCLeptomeningeal Metastasis
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Second Affiliated Hospital of Nanchang University
- Target Recruit Count
- 69
- Registration Number
- NCT04944069
- Locations
- 🇨🇳
The Second Afiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: AlmonertinibRadiation: Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Chongqing University Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04905550
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04882345
Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 232
- Registration Number
- NCT04870190
MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 192
- Registration Number
- NCT04841811
- Locations
- 🇨🇳
Guangdong Lung cancer institute, Guangzhou, Guangdong, China
Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT04808752
- Locations
- 🇨🇳
Cancer Hospital Affiliated to University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 40
- Registration Number
- NCT04785742
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guang Dong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.